Bolt Biotherapeutics, Inc. BOLT
6.41 USD -0.13 (-1.99%)
Nov 9, 2026, 1:26 PM EST
6.10 Day range 6.57
3.10 52-week range 7.78
- YTD
- +17.18%
- 1 year
- +40.88%
News
globenewswire.com INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU? NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and…
prnewswire.com INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU? /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for
globenewswire.com Bolt Biotherapeutics to Participate in Upcoming Conferences REDWOOD CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”), a clinical-stage biotechnology company pioneering a new generation of…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics…
benzinga.com Bolt’s Acquisition Positions It To Advance Prana’s Inspire Multispecific Antibody Pipeline; Phase 2 PRA-216 Readouts Expected Starting Q2 2027 Prana’s Pipeline Overview and Development MilestonesPrana’s focus is to develop the next generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. The…
benzinga.com Bolt Biotherapeutics Secures $120M Private Placement, With Potential Additional $60M From Warrant Exercise To Fund Operations Into 2028 Concurrent with the acquisition, Bolt entered into a definitive agreement for a private placement financing to raise $120 million in gross proceeds, for the purchase of 13,995.311 shares of Series D…
benzinga.com Bolt Biotherapeutics Acquires Prana Therapies In Sign-And-Close Reverse Merger, Shifts Focus To Multispecific Antibody Pipeline; Prana Holders to Own 51.7% of Combined Company, Backed by Up To $180M Financing Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platform PRA-216 is a novel…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular session. The market value of their outstanding shares is at $9.5 million. Sionna Therapeutics (NASDAQ:SION)…
benzinga.com Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K Estimate Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent. This is a 2.47 percent decrease over losses…
benzinga.com Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22 Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $22.- benzinga.com HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.
benzinga.com Bolt Biotherapeutics Q1 EPS $(4.31) Misses $(2.85) Estimate, Sales $26.000K Miss $1.500M Estimate Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.31) per share which missed the analyst consensus estimate of $(2.85) by 51.23 percent. This is a 25.69 percent increase over losses…- benzinga.com HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.
- benzinga.com Bolt Biotherapeutics Q4 EPS $(3.84) Beats $(4.30) Estimate, Sales $2.500M Beat $666.667K Estimate Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(3.84) per share which beat the analyst consensus estimate of $(4.30) by 10.7 percent. This is a 49.47 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Bolt Biotherapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS (FOR THE TREATMENT OF CANCER)". https://x.com/PatentGrants/status/1998150771544928598?s=20
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
benzinga.com Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 112 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's session, 406 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 210 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 152 stocks made new 52-week lows.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 435 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 721 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 431 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 236 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 160 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 242 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 466 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's morning session, 234 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 671 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 313 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 615 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday During the morning session on Thursday, 152 stocks hit new 52-week lows.- benzinga.com 101 Biggest Movers From Friday Gainers Atlantic American Corporation. (NASDAQ: AAME) shares surged 117.6% to close at $5.20 on Friday after surging over 5% on Thursday.